Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating four different isotonic and hypertonic seawater-based nasal sprays in real-life settings for their effectiveness, safety, usage, tolerance, and user satisfaction. The study focuses on infants, children, adults, and pregnant or breastfeeding women who have acute or chronic sinonasal conditions such as upper respiratory tract infections, allergic rhinitis, chronic rhinosinusitis, bronchiolitis, COVID-19, and post-surgery nasal issues. The investigation aims to understand how these devices perform when used as intended across various patient groups. Participants will use one of four CE-marked nasal spray devices according to their specific indications and target populations. The sprays include Respimer Hygiene-Prevention for babies, kids, and adults, Respimer Decongestion for babies from two months old and older, and Phytosun arms Hypertonic nasal wash for children six years and older and adults. Usage instructions vary by product, ranging from 1 to 6 sprays per nostril daily, with different frequencies for treatment and prevention purposes. The study period covers up to three months to assess both short-term and longer-term effects. During the study, participants or their parents will complete online questionnaires and follow healthcare providers advice on nasal wash techniques. Researchers will monitor nasal symptom changes, including intensity and frequency, improvement in nasal breathing, quality of life, and satisfaction with the sprays. Effectiveness will be evaluated from day 0 to day 5 for acute conditions and up to day 14 for chronic issues, extending to three months for seasonal symptom management. Safety, tolerance, and usage patterns will also be recorded throughout the study.
Actively Recruiting
This research evaluates whether non-invasive vagal stimulation can better prevent chemotherapy-induced nausea in breast cancer patients undergoing cyclophosphamide and anthracycline treatment. Chemotherapy-induced nausea remains common and negatively impacts quality of life despite existing medications. Non-invasive vagal stimulation is approved for other conditions like headache and gastroparesis and may reduce nausea. Participants receive standard antiemetic treatment along with either active non-invasive auricular vagal stimulation or a sham stimulation twice daily, starting the day before chemotherapy until four days after, during the first three chemotherapy cycles. The stimulation uses a transcutaneous auricular device to assess if adding this method improves nausea control compared to standard care alone. Throughout the study, participants are monitored for nausea occurrence after each chemotherapy cycle, vomiting, use of rescue medications, emergency visits, hydration needs, and hospitalizations related to nausea. Quality of life questionnaires specific to breast cancer and general health are completed during the first three cycles. Safety and side effects related to vagal stimulation are also evaluated. The trial measures outcomes over up to 12 weeks, with primary focus on nausea after the first chemotherapy cycle.
Actively Recruiting
Researchers are evaluating the safety and clinical performance of the Dexter Robotic System in patients undergoing robotic-assisted right colectomy. The study aims to confirm the devices safety during the perioperative and early postoperative periods, focusing on its use in right colectomy procedures. The sponsor for this observational study is Distalmotion SA. Participants will undergo a robotic-assisted right colectomy using the Dexter Robotic Surgery System. The study observes the surgical procedure and monitors patients without assigning treatments, as it is observational in nature. There are no comparator groups or placebo treatments involved. During the study, participants will be followed for safety outcomes up to 30 days after surgery, and efficacy will be assessed during the operation itself. Follow-up assessments as per standard care will be performed to monitor recovery and any potential complications. Total study participation lasts through the surgery and the 30-day postoperative period.
Actively Recruiting
Researchers are conducting an observational, multicenter study focusing on patients with non-small cell lung cancer NSCLC who are starting treatment with approved drugs developed by AstraZeneca or its alliance partners. The study includes three patient groups based on disease stage resectable, unresectable, and metastatic NSCLC. This modular study evaluates these treatments as monotherapy or in combination across various disease stages once European marketing authorization is granted and the drugs are available in the participating countries. Participants receive treatments independently decided by their doctors before joining the study, without any changes made by the research team. The study collects data retrospectively and prospectively on patients who have received, are receiving, or will receive these approved drugs. Each cohort reflects real-world use of AstraZeneca or alliance-developed drugs in different NSCLC stages, with no experimental intervention assigned by the study. During the study, researchers collect information on disease progression, treatment responses, and survival over three years, including measures such as real-world disease-free survival and time to treatment failure. Data on response rates and additional survival outcomes are also gathered. Participants health and treatment outcomes are monitored through routine clinical data collection and follow-up, contributing to a better understanding of these treatments in everyday clinical practice.